the company called adherence.

Integrating the #MMAS Platform into your clinical practice is not just a smart choice—it's a proven strategy for improving patient care. Studies have shown that nurse-led and pharmacist-led interventions significantly enhance medication adherence, which directly correlates with better health outcomes. The MMAS Platform equips your team with an evidence-based tool to identify patients at risk for non-adherence through eight simple questions, allowing for timely and targeted interventions. By using MMAS, your nurses and pharmacists can be that catalyst in ensuring patients stay on track with their treatment plans. The impact of improved adherence is undeniable: when patients consistently follow their prescribed regimens, they experience fewer complications, reduced hospitalizations, and overall better health. With the MMAS Platform integrated into your practice, you'll tap into the power of evidence-based practice to drive these outcomes. This is about elevating the standard of care you provide; providing your team with tools that make a real difference.

🎉 Adherence is headed to HLTH USA in Las Vegas! 🎉 We can’t wait to show you how AI and the #MMAS are transforming medication adherence. And we are not talking about ai chatbots. This is machine learning 100xl. Get hands-on with live demos of our powerful tools, learn how we're using AI to drive better patient outcomes, and discover the future of healthcare innovation. And don't miss the chance to meet Chief Optimus Philip Morisky, MBA, Ξ in person! 🤝 This is the place to connect, learn, and see how we’re revolutionizing adherence management. See you there! #HLTH2024 #MMAS #HealthcareInnovation #MedicationAdherence #AIinHealthcare #LasVegas #AdherenceSolutions #MeetTheOptimus

Ai Prompt: How many patients does Aetna Medicaid serve? Response: Aetna Medicaid, through its various state programs, serves over 2.8 million beneficiaries across 16 states. This figure reflects its extensive reach in providing managed care services to Medicaid members, encompassing populations such as low-income adults, children, pregnant women, and individuals with disabilities【137†source】【138†source】. Aetna's #Medicaid plans are designed to deliver comprehensive healthcare services, emphasizing preventive care and care coordination. The increasing focus on Star Ratings is putting pressure on healthcare providers and insurance companies to find innovative ways to improve medication adherence, a key metric in these ratings. With non-adherence affecting patient outcomes and driving up costs, insurance companies are actively seeking new solutions to better manage and optimize adherence. This is where tools like the #MMAS and AI-driven insights come in, offering a data-backed approach to track, improve, and manage adherence effectively. The push to improve these ratings is sparking fresh ideas and strategies—leading the charge in this space will mean better outcomes for both patients and providers. 💡 Aetna, a CVS Health Company CVS Health CVS Specialty

🚀 Got a Telehealth or RPM platform but struggling to track which patients aren’t taking their meds as prescribed? We’ve got you covered! With the #MMAS API/web service or hosting options, your platform can instantly benefit from this intuitive, proven solution. 🛠️ Imagine asking the right questions, identifying adherence issues in real time, and developing personalized treatment plans—all seamlessly integrated into your system. Ready to take patient care to the next level? Let’s get started! BUT DON'T JUST TAKE MY WORD FOR IT!!! FIND OUT WHY CVS Specialty HAS BEEN USING IT EVERY DAY FOR THE PAST 8 YEARS AND HOW Asembia INTEGRATED IT DIRECTLY ONTO THEIR Asembia-1 PLATFORM. CVS Health 🚨 I’ll be at the HLTH USA conference next week! 🚨 Excited to show live demos of how the MMAS API and our powerful tools can transform medication adherence in Telehealth and RPM platforms. From asking the right questions to personalizing treatment plans, this solution will empower your platform to deliver better patient care and outcomes. Grab a spot, check out the demos, and see how we’re changing the game! 💥 Let’s connect! #HLTH2024 🔥 #Telehealth #RPM #MMAS #MedicationAdherence #DigitalHealth #HealthcareInnovation #PatientOutcomes

At the 2024 ESMO - European Society for Medical Oncology Congress, a number of fascinating studies were presented, including new insights on the connection between medication adherence and outcomes in breast cancer treatment. One study I want to highlight, which the #mmas played a major part in, of 500 breast cancer patients showed that adherence to oral anticancer medications varies significantly depending on whether patients had metastatic or nonmetastatic cancer. Patients with metastatic cancer showed higher adherence, while those with nonmetastatic cancer had a much lower rate of adherence—only 28.3% based on the Morisky Medication Adherence Scale. The study also found that severe side effects—like pain, fatigue, and hot flashes—were closely linked to lower adherence. Interestingly, shorter treatment durations were associated with better adherence. The researchers at the National Cancer Institute -Cairo University and Helwan University Cairo developed an adherence program. For 6 months, pharmacy follow up visits were scheduled for patient education, toxicity monitoring and supportive care management. We see the urgency to provide more support and education for patients, especially those managing difficult side effects, in order to improve adherence. El-Shewy R, Ebid A-HIM, Mobarez MA, et al. Evaluating adherence to oral anticancer medications in metastatic and nonmetastatic breast cancer patients. . Presented at: European Society of Medical Oncology; September 13-17, 2024; Barcelona, Spain. Abstract 376P. Rana Elshewy Emad Shash Abdel-Hameed Mohammed Ebid Mohammed Mobarez the company called adherence. #ESMO2024 #BreastCancerAwareness #MedicationAdherence #PatientSupport #Oncology

🚨 Big things are happening at Adherence Labs! 🚨 We're talking AI and Machine Learning in medication adherence—but not just your typical chatbot interventions. Imagine...well, I can't say it just yet. 🗺️🌍 And yes, the MMAS will be central to identifying patterns and driving real impact. This isn’t the future—it’s happening now. Soon, you'll unlock insights from worldwide studies, transforming how we tackle non-adherence. 👀 Stay tuned—what we’ve got in store will change the game! 🔥 #AIinHealthcare #MMAS #MachineLearning #MedicationAdherence #HealthcareInnovation #AdherenceLabs #BigData

🚨 Exciting News! 🚨 I am so pumped to attend HLTH USA NV next week! 🙌 This week, I am finalizing and arrange meetings/ carving out time to walk the floor, meet with new faces, and catch up with LinkedIn connections in person! 🤝 But that’s not all... There are #BIG announcements coming your way, and you won’t want to miss the live demos of the digital #MMAS and interventional tools paired with #AI. 🚀 Stay tuned for the latest innovations in medication adherence and patient care! Let’s connect if you’ll be there too—this is going to be an unforgettable week! 💥 #HLTH2024 #HealthcareInnovation #MedAdherence #DigitalHealth #Networking

On Metastatic Breast Cancer Awareness Day, I post in order to remind everyone of the ongoing challenges patients face in managing their treatment. In my ongoing efforts to promote adherence, I am so excited to share with you a cutting-edge clinical trial that leverages machine learning and decision support systems to improve medication adherence for those battling metastatic breast cancer. I’ve been working with researchers at the University of Milan on this project for a while. 📢Leveraging Machine Learning to Enhance Medication Adherence for Metastatic Breast Cancer Patients I’m excited to share this RCT that’s pushing the boundaries of healthcare innovation. This study explores a machine learning model designed to predict patient adherence behavior and integrates a decision support system (DSS) to improve outcomes for patients with metastatic breast cancer (MBC). 🎯 Primary Goal: The trial aims to evaluate the effectiveness of a web-based DSS and machine learning application in promoting adherence to oral anticancer therapies (OATs) over 3 months. The adherence will be tracked by the number of pills taken versus the number prescribed. Most importantly, adherence behavior will be measured using the well-established 8-item Morisky Medication Adherence Scale (#MMAS-8) and the Adherence Attitude Inventory (AAI). By combining predictive analytics and personalized decision support, this trial could reshape how we approach treatment adherence, empowering patients to stay on track with their therapies and ultimately improving outcomes. Stay tuned as we continue to explore how data-driven solutions can transform care for patients with metastatic breast cancer. Abstract in comments section. This will surely lead to new opportunities. #HealthcareInnovation #MachineLearning #ClinicalTrials #BreastCancer #MedicationAdherence #DSS #PatientOutcomes #MMAS #OAT

Epilepsy remains a significant global health burden, affecting 1% of the world’s population – with the highest rates in sub-Saharan Africa. To address this challenge, Jane von Gaudecker, PhD, RN, and associate professor at the IU School of Nursing, is leading a groundbreaking study, “Bridging the Treatment Gap by Expanding Access to Care for People with Epilepsy in Kenya” (BEACON), thanks to a $2.4 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and the Fogarty International Center at NIH. “Epilepsy is a condition steeped in myths and misconceptions,” von Gaudecker explained. “Some people believe it’s contagious, or caused by witchcraft, which makes it difficult for patients to seek treatment. Through this initial intervention study aimed at addressing the epilepsy treatment gap in western Kenya, we will begin by training healthcare professionals. Our aim is to shift these attitudes and enhance the quality of care for people with epilepsy.” Learn more: https://ow.ly/lb8a50TAAT0

“Only what gets measured gets managed.” – Peter Drucker’s timeless insight is relevant more than ever in healthcare today, especially as we look at the evolving importance of medication adherence. With the new Medicare Star Ratings, medication adherence is more critical than ever, with a heightened focus on managing patient outcomes. The shift in weightings highlights not only the need but the opportunity for a proactive approach. It’s time to change the thought process. Measuring adherence through tools like the Morisky Medication Adherence Scale (#MMAS) isn’t just a checkbox—it’s about identifying barriers and creating tailored, self-management solutions for patients. By measuring adherence, we uncover underlying behaviors and provide personalized strategies to improve patient outcomes. This isn’t just about compliance; it’s about empowering patients to take control of their health. The MMAS helps surface concerns—whether it’s forgetfulness, side effects, or treatment complexity—and allows healthcare providers to intervene with precision. In this new landscape, it’s clear: managing what we measure drives meaningful change in healthcare. Let’s leverage these tools to build healthier communities and stronger patient-provider partnerships. #MedicationAdherence #StarRatings #PatientOutcomes #ProactiveCare